Remove Clinical Development Remove Drug Development Remove Webinar
article thumbnail

Leveraging AI Solutions for Clinical Trial Efficiencies

PPD

As a result, drug developers make better decisions more quickly (removing 50% of study timeline whitespace) to bring new therapies to market faster. Ready to learn more about how to leverage AI and machine learning to maximize your clinical trial efficiency? Get in touch.

article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

billion buyout of Blueprint Medicines is the sector’s second-largest M&A deal this year and represents the highest value paid for an immune drug developer since April 2023. Sanofi’s $9.1 Sanofi’s $9.1

FDA 269
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Soleno sales of new Prader-Willi drug rise faster than expected

BioPharma Drive: Drug Pricing

Until Vykat came along, though, no drug therapies were specifically approved to curb the all-consuming hunger that hallmarks the condition. The drug’s clearance came after an unusual clinical development journey and, in the ensuing months, has swelled Soleno’s market value past $4 billion amid optimism about the drug’s sales prospects.

Drugs 215
article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

Expertise that accelerates your clinical development success The PPD clinical research business of Thermo Fisher Scientific has significant experience in customized Phase I-IV metabolic clinical trials. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.

article thumbnail

Harnessing AI and Real-World Data: The Future of Clinical Development

PPD

The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. In a recent panel discussion at DIA Global , our experts explored how these elements are reshaping clinical research and drug discovery.

article thumbnail

Webinar— A Square Peg in a Round Hole–Navigating the Unique Attributes of Psychedelic Drug Development

Alta Sciences

Webinar— A Square Peg in a Round Hole–Navigating the Unique Attributes of Psychedelic Drug Development iianiro Fri, 08/18/2023 - 19:49 URL [link] Description Save the date—Join us for a complimentary webinar for an overview of the draft FDA guidance on early-phase clinical development of psychedelics and how Altasciences can guide you through the process, (..)

article thumbnail

Webinar: Assessing Cognition Impairment Using Driving Simulators in Clinical Trials

Alta Sciences

The FDA guidance, Evaluating Drug Effects on the Ability to Operate a Motor Vehicle , indicates that testing in early-phase clinical development should emphasize sensitivity over specificity in CNS effects. In this on-demand webinar, Ingrid Holmes , Vice President of Global Clinical Operations at Altasciences, and Dr. Gary G.